# OnCo record leukostrat-cdx-flt3 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/leukostrat-cdx-flt3/>
  a schema:MedicalTest ;
  onco:kind "drug" ;
  schema:identifier "leukostrat-cdx-flt3" ;
  schema:name "LeukoStrat CDx FLT3 Mutation Assay"@en ;
  schema:description "The FDA-approved test that decides whether a person with acute myeloid leukaemia has a FLT3 mutation and so can be offered a FLT3 inhibitor."@en ;
  schema:url <https://onco.cc/drugs/leukostrat-cdx-flt3/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160040>, <https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools>, <https://invivoscribe.com/about-us/> ;
  onco:status "approved" ;
  onco:tag "test" ;
  onco:modality "PCR companion diagnostic test (FLT3 ITD and TKD mutations, blood or bone marrow)" ;
  schema:alternateName "LeukoStrat CDx FLT3" ;
  onco:approval "US 2017: Companion diagnostic for midostaurin in acute myeloid leukaemia (FLT3 ITD and TKD)", "US 2018: Companion diagnostic for gilteritinib", "US 2023: Companion diagnostic for quizartinib" ;
  onco:related <https://onco.cc/biomarkers/flt3-itd/>, <https://onco.cc/biomarkers/flt3-tkd/> ;
  onco:cancers <https://onco.cc/cancers/aml/> ;
  onco:technologies <https://onco.cc/technologies/companion-diagnostic/> ;
  onco:targets <https://onco.cc/targets/flt3/> ;
  onco:drugs <https://onco.cc/drugs/midostaurin/>, <https://onco.cc/drugs/gilteritinib/>, <https://onco.cc/drugs/quizartinib/> ;
  onco:companies <https://onco.cc/companies/invivoscribe/> ;
  onco:terms <https://onco.cc/terms/pcr/>, <https://onco.cc/terms/companion-diagnostic-term/> .